Cytokinetics (CYTK) Non-Current Debt (2016 - 2024)
Historic Non-Current Debt for Cytokinetics (CYTK) over the last 11 years, with Q3 2024 value amounting to $93.0 million.
- Cytokinetics' Non-Current Debt rose 5277.49% to $93.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $93.0 million, marking a year-over-year increase of 5277.49%. This contributed to the annual value of $58.4 million for FY2023, which is 850.34% down from last year.
- As of Q3 2024, Cytokinetics' Non-Current Debt stood at $93.0 million, which was up 5277.49% from $92.8 million recorded in Q2 2024.
- Cytokinetics' Non-Current Debt's 5-year high stood at $93.0 million during Q3 2024, with a 5-year trough of $30.2 million in Q3 2021.
- In the last 5 years, Cytokinetics' Non-Current Debt had a median value of $58.4 million in 2023 and averaged $56.7 million.
- In the last 5 years, Cytokinetics' Non-Current Debt tumbled by 3422.69% in 2021 and then skyrocketed by 11038.97% in 2022.
- Cytokinetics' Non-Current Debt (Quarter) stood at $46.2 million in 2020, then grew by 2.51% to $47.4 million in 2021, then soared by 34.71% to $63.8 million in 2022, then dropped by 8.5% to $58.4 million in 2023, then skyrocketed by 59.32% to $93.0 million in 2024.
- Its Non-Current Debt was $93.0 million in Q3 2024, compared to $92.8 million in Q2 2024 and $56.8 million in Q1 2024.